Sharon Sawchak

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

Michael Gold, Claire Alderton, Marina Zvartau‐Hind et al. · Dementia and Geriatric Cognitive Disorders · 2010 · 347 citations · Full text

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia

Stephen K. Brannan, Sharon Sawchak, Andrew Miller et al. · New England Journal of Medicine · 2021 · 308 citations · Full text

Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies

Conn Harrington, Sharon Sawchak, Carl Chiang et al. · Current Alzheimer Research · 2011 · 192 citations

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

Inder Kaul, Sharon Sawchak, Christoph U. Correll et al. · The Lancet · 2023 · 192 citations

Flexible-dose Phase 3, Psychiatry, Psychotic Disorder +9

Continuously updated 12-lead ST-segment recovery analysis for myocardial infarct artery patency assessment and its correlation with multiple simultaneous early angiographic observations

Mitchell W. Krucoff, Martha A. Croll, James E. Pope et al. · The American Journal of Cardiology · 1993 · 165 citations

Vascular Image, Cardiovascular Disease, Atherosclerosis +11